NASDAQ$CMPX
Compass Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported full year 2023 financial results and provided business update.
Compass Therapeutics reported a net loss of $42.5 million for the year ended December 31, 2023, and ended the year with $152.5 million in cash and marketable securities, extending the cash runway into mid-2026. The company is focused on clinical development of CTX-009 and expects to report top-line data from Phase 2 trials by mid and end of the year.
- Strategically shifted focus toward clinical development of CTX-009.
- Expects to report top-line data from Stage 1 of the Phase 2 COMPANION-003 trial by mid-year.
- Expects to report top-line data from Phase 2/3 COMPANION-002 trial by the end of the year.
- Ended the year with $152.5 million, extending cash runway into the middle of 2026.
Headline financials
Revenue & EPS history
Compass · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
-1.9%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.4%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+10.3%
Q1 2023
Best reaction
-17.6%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.0% | -2.1% | -4.2% | |
| Q3 2025 | +1.1% | +12.9% | +45.9% | |
| Q1 2025 | +4.0% | +2.0% | +19.3% | |
| Q4 2024 | -1.7% | -6.4% | -33.0% | |
| Q3 2024 | -11.1% | -27.4% | -20.5% | |
| Q2 2024 | +10.1% | +6.4% | +37.6% | |
| Q1 2024 | +1.3% | +0.0% | -25.0% | |
| Q4 2023 | +0.5% | -6.6% | -30.7% | |
| Q3 2023 | -9.9% | -11.0% | +1.2% | |
| Q2 2023 | -3.8% | -5.3% | -9.2% | |
| Q1 2023 | +10.3% | +13.3% | -1.8% | |
| Q4 2022 | -5.0% | -10.8% | -13.9% | |
| Q3 2022 | -4.0% | +10.4% | +1.4% | |
| Q2 2022 | +1.2% | +2.3% | +5.8% | |
| Q1 2022 | -3.0% | +50.3% | +63.9% | |
| Q4 2021 | +6.2% | +4.6% | +20.8% | |
| Q3 2021 | +0.3% | +7.2% | -16.2% | |
| Q2 2021 | -11.9% | -6.0% | -16.7% | |
| Q1 2021 | -17.6% | -17.6% | -50.6% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro